3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
5
Neoplasms
2
Thrombosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
fludarabine phosphate
16
Cyclophosphamide
15
Peripheral Blood Stem Cell Transplantation
10
Tacrolimus
9
Busulfan
9
Whole-Body Irradiation
8
Mycophenolic Acid
8
fludarabine
6
Methotrexate
6
Cyclosporine
6
Radiotherapy
5
ruxolitinib
4
Biopsy
4
Antilymphocyte Serum
4
Specimen Handling
3
Decitabine
3
peginterferon alfa-2a
2
givinostat hydrochloride
2
givinostat
2
bomedemstat
2
Stem Cell Transplantation
2
Prednisone
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
Methylprednisolone
2
Melphalan
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Cytarabine
2
Aspirin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thrombocythemia, Essential
×
apixaban
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled